Cargando…

Oral maintenance therapy using apatinib combined with S-1/capecitabine for esophageal squamous cell carcinoma with residual disease after definitive chemoradiotherapy

Background: A substantial number of patients with esophageal squamous cell carcinoma (ESCC) do not achieve complete remission after definitive concurrent chemoradiotherapy (dCRT). We performed this retrospective study to evaluate the efficacy and safety of apatinib combined with S-1/capecitabine as...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chi, Dongmei, Chen, Baoqing, Guo, Suping, Bai, Kunhao, Ma, Huali, Hu, Yonghong, Li, Qiaoqiao, Zhu, Yujia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8034932/ https://www.ncbi.nlm.nih.gov/pubmed/33713398 http://dx.doi.org/10.18632/aging.202652

Ejemplares similares

Definitive concurrent chemoradiotherapy with docetaxel plus cisplatin versus 5-fluorouracil plus cisplatin in patients with esophageal squamous cell carcinoma: long-term follow-up results of a phase II randomized controlled trial
por: Jiang, Hui, et al.
Publicado: (2023)

Induction chemotherapy followed by definitive chemoradiotherapy versus chemoradiotherapy alone in esophageal squamous cell carcinoma: a randomized phase II trial
por: Liu, Shiliang, et al.
Publicado: (2021)

Definitive Chemoradiotherapy with Capecitabine and Cisplatin in Patients with Esophageal Cancer: A Pilot Study
por: Lee, Soo Jung, et al.
Publicado: (2009)

A phase II clinical trial of toripalimab combined with neoadjuvant chemoradiotherapy in locally advanced esophageal squamous cell carcinoma (NEOCRTEC1901)
por: Chen, Rui, et al.
Publicado: (2023)

Prediction of Pathologic Response to Neoadjuvant Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma Incorporating Hematological Biomarkers
por: Wu, Yingjia, et al.
Publicado: (2021)

Endoscopic resection for local residual or recurrent cancer after definitive chemoradiotherapy or radiotherapy for esophageal squamous cell carcinoma
por: Tani, Yasuhiro, et al.
Publicado: (2023)

A Phase II Randomized Controlled Trial: Definitive Concurrent Chemoradiotherapy with Docetaxel Plus Cisplatin versus 5-Fluorouracil plus Cisplatin in Patients with Oesophageal Squamous Cell Carcinoma
por: Zhu, Yujia, et al.
Publicado: (2017)

Phase I study of cisplatin and nanoparticle albumin‐bound‐paclitaxel combined with concurrent radiotherapy in locally advanced esophageal squamous cell carcinoma
por: Jiang, Hui, et al.
Publicado: (2023)

Salvage treatment after definitive chemoradiotherapy for esophageal squamous cell carcinoma
por: Yagi, Koichi, et al.
Publicado: (2021)

Characteristics and Treatment of Brain Metastases from Esophageal Squamous Cell Carcinoma
por: Li, Qiaoqiao, et al.
Publicado: (2018)

The Safety and Efficacy of Apatinib Treatment in Addition to Concurrent Chemoradiotherapy in Patients with Nonoperative Locally Advanced Esophageal Squamous Cell Carcinoma
por: Hu, Lijun, et al.
Publicado: (2020)

Comparative Outcomes of Induction Chemotherapy Followed By Definitive Chemoradiotherapy versus Chemoradiotherapy Alone In Esophageal Squamous Cell Carcinoma
por: Luo, Li-Ling, et al.
Publicado: (2017)

TNM Staging Matched-pair Comparison of Surgery After Neoadjuvant Chemoradiotherapy, Surgery Alone and Definitive Chemoradiotherapy for Thoracic Esophageal Squamous Cell Carcinoma
por: Liu, ShiLiang, et al.
Publicado: (2017)

Radiotherapy for small cell carcinoma of the esophagus: outcomes and prognostic factors from a retrospective study
por: Chen, Baoqing, et al.
Publicado: (2019)

Involved-field irradiation in definitive chemoradiotherapy for locally advanced esophageal squamous cell carcinoma
por: Zhang, Xiaoli, et al.
Publicado: (2014)

Effect of consolidation chemotherapy following definitive chemoradiotherapy in patients with esophageal squamous cell cancer
por: Wu, Sheng-Xi, et al.
Publicado: (2017)

Recent Advances in Combination of Immunotherapy and Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
por: Wang, Ruixi, et al.
Publicado: (2022)

Propensity score analysis comparing survival between definitive chemoradiotherapy and esophagectomy with adjuvant chemoradiotherapy in patients with esophageal squamous cell carcinoma
por: Chang, Yi-Lin, et al.
Publicado: (2022)

Clinical Prognostic Factors for Locally Advanced Esophageal Squamous Carcinoma Treated after Definitive Chemoradiotherapy
por: Kim, Dae-Eun, et al.
Publicado: (2013)

Neoadjuvant vs definitive concurrent chemoradiotherapy in locally advanced esophageal squamous cell carcinoma patients
por: Chen, Chih-Yi, et al.
Publicado: (2018)

Adjuvant chemotherapy does not benefit patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy
por: Chen, Mingqiu, et al.
Publicado: (2018)

FGF5 methylation is a sensitivity marker of esophageal squamous cell carcinoma to definitive chemoradiotherapy
por: Iwabu, Jun, et al.
Publicado: (2019)

Long-term results of definitive chemoradiotherapy for unresectable locally advanced esophageal squamous cell carcinoma
por: Ochi, Masanori, et al.
Publicado: (2020)

A nomogram for the predicting of survival in patients with esophageal squamous cell carcinoma undergoing definitive chemoradiotherapy
por: Wang, Peiliang, et al.
Publicado: (2021)

Chemoradiotherapy Combined with Brachytherapy for the Definitive Treatment of Esophageal Carcinoma
por: Mangesius, Julian, et al.
Publicado: (2023)

Efficacy and safety of apatinib treatment for advanced esophageal squamous cell carcinoma
por: Li, Jianqiang, et al.
Publicado: (2017)

Lymph node enlargement after definitive chemoradiotherapy for clinical stage I esophageal squamous cell carcinoma
por: Hayashi, Yoshito, et al.
Publicado: (2014)

Murine double minute 2 predicts response of advanced esophageal squamous cell carcinoma to definitive chemoradiotherapy
por: Okamoto, Hiroshi, et al.
Publicado: (2015)

Improved survival with higher radiation dose for esophageal squamous cell carcinoma patients treated with definitive chemoradiotherapy
por: Deng, Yuxia, et al.
Publicado: (2017)

YAP1 amplification as a prognostic factor of definitive chemoradiotherapy in nonsurgical esophageal squamous cell carcinoma
por: Dai, Honghai, et al.
Publicado: (2019)

Prediction of outcome with FDG-PET in definitive chemoradiotherapy for esophageal cancer
por: Atsumi, Kazushige, et al.
Publicado: (2013)

Evaluating the optimal radiation dose for definitive chemoradiotherapy for esophageal squamous cell carcinoma: A single institution experience
por: Ke, Te-Min, et al.
Publicado: (2018)

Primary tumor regression patterns in esophageal squamous cell cancer treated with definitive chemoradiotherapy and implications for surveillance schemes
por: Chen, Mingqiu, et al.
Publicado: (2019)

Prognostic Significance of Interim Response Evaluation during Definitive Chemoradiotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma
por: Yeom, Jun Gi, et al.
Publicado: (2021)

Prognostic value of pre-therapeutic nutritional risk factors in elderly patients with locally advanced esophageal squamous cell carcinoma receiving definitive chemoradiotherapy or radiotherapy
por: Qiu, Jianjian, et al.
Publicado: (2023)

M(1)A and m(7)G modification-related genes are potential biomarkers for survival prognosis and for deciphering the tumor immune microenvironment in esophageal squamous cell carcinoma
por: Wang, Ruixi, et al.
Publicado: (2023)

Neoadjuvant Chemoradiotherapy and Surgery for Esophageal Squamous Cell Carcinoma Versus Definitive Chemoradiotherapy With Salvage Surgery as Needed: The Study Protocol for the Randomized Controlled NEEDS Trial
por: Nilsson, Magnus, et al.
Publicado: (2022)

Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study
por: Li, Yi-Hui, et al.
Publicado: (2018)

VEGF as a Predictor for Response to Definitive Chemoradiotherapy and COX-2 as a Prognosticator for Survival in Esophageal Squamous Cell Carcinoma
por: Yoon, Mee Sun, et al.
Publicado: (2011)

THRB Genetic Polymorphisms Can Predict Severe Myelotoxicity after Definitive Chemoradiotherapy in Patients with Esophageal Squamous Cell Carcinoma
por: Miki, Ikuya, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_0h49bcgjb9rjqmi0n27h7c5r9u